Stille W
Wien Klin Wochenschr Suppl. 1983;142:18-20.
Our clinical experience with new antibiotics giving special consideration to the individual cephalosporin groups is discussed. Although newer cephalosporins from cefamandol and cefoxitin to cefotiam and cefoperazon already showed increased effectiveness (for example, cefoxitin in bacteroides infection) in comparison to older ones, the real breakthrough regarding enterobacteriaceae was only made with cephalosporins of the cefotaxime group. This group's main indication is non-specific initial therapy of severe nosocomial infections, especially processes in which the presence of resistant enterobacteriaceae must be assumed. Because of its broad spectrum of action, cefotaxime can to a large extent replace the combinations with aminoglycosides which were used previously. When required, cefotaxime proves to be a good partner for combinations with pseudomonas antibiotics.
我们讨论了新型抗生素的临床经验，特别考虑了各个头孢菌素组。尽管从头孢孟多和头孢西丁到头孢替安和头孢哌酮的新型头孢菌素与旧型头孢菌素相比已显示出更高的有效性（例如，头孢西丁在拟杆菌感染中的应用），但关于肠杆菌科细菌的真正突破仅在头孢噻肟组的头孢菌素中实现。该组的主要适应症是严重医院感染的非特异性初始治疗，特别是那些必须假定存在耐药肠杆菌科细菌的情况。由于其广泛的抗菌谱，头孢噻肟在很大程度上可以取代以前使用的与氨基糖苷类药物的联合用药。在需要时，头孢噻肟被证明是与假单胞菌属抗生素联合使用的良好搭档。
